BAVARIAN NORDIC logoBavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus. In addition, the company is developing PROSTVAC, which is in Phase III clinical development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer; CV301 that is in Phase II clinical trial for the treatment multiple cancers; and MVA-BN Brachyury that has completed Phase I clinical trial for the treatment of metastatic cancer. The company has collaboration agreements with National Cancer Institute; Bristol-Myers Squibb; Janssen Pharmaceuticals, Inc.; and Biomedical Advanced Research and Development Authority. It also has a license and collaboration agreement with Janssen Pharmaceuticals, Inc. to leverage its MVA-BN technology with Janssen’s AdVac and DNA-based vaccine technologies for the development and commercialization of new vaccine regimens against hepatitis B virus (HBV) and human immunodeficiency virus (HIV-1). The company operates in the United States, Holland, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is headquartered in Kvistgaard, Denmark.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $1.36375 billion
  • Outstanding Shares: 94,432,000
Average Prices:
  • 50 Day Moving Avg: $11.70
  • 200 Day Moving Avg: $11.70
  • 52 Week Range: $10.44 - $22.70
  • Trailing P/E Ratio: 263.23
  • Foreward P/E Ratio: 12.24
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $236.21 million
  • Price / Sales: 5.68
  • Book Value: $3.63 per share
  • Price / Book: 3.91
  • EBIDTA: $61.58 million
  • Net Margins: 15.48%
  • Return on Equity: 11.16%
  • Return on Assets: 7.96%
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 2.87%
  • Quick Ratio: 2.70%
  • Average Volume: 70 shs.

Frequently Asked Questions for BAVARIAN NORDIC (OTCMKTS:BVNRY)

What is BAVARIAN NORDIC's stock symbol?

BAVARIAN NORDIC trades on the OTCMKTS under the ticker symbol "BVNRY."

How were BAVARIAN NORDIC's earnings last quarter?

BAVARIAN NORDIC (OTCMKTS:BVNRY) issued its quarterly earnings data on Friday, August, 25th. The company reported $0.07 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.14 by $0.07. The company had revenue of $58.68 million for the quarter, compared to the consensus estimate of $50.65 million. BAVARIAN NORDIC had a return on equity of 11.16% and a net margin of 15.48%. View BAVARIAN NORDIC's Earnings History.

When will BAVARIAN NORDIC make its next earnings announcement?

BAVARIAN NORDIC is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for BAVARIAN NORDIC.

Who are some of BAVARIAN NORDIC's key competitors?

How do I buy BAVARIAN NORDIC stock?

Shares of BAVARIAN NORDIC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BAVARIAN NORDIC's stock price today?

One share of BAVARIAN NORDIC stock can currently be purchased for approximately $14.20.

MarketBeat Community Rating for BAVARIAN NORDIC (OTCMKTS BVNRY)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  59 (Vote Outperform)
Underperform Votes:  25 (Vote Underperform)
Total Votes:  84
MarketBeat's community ratings are surveys of what our community members think about BAVARIAN NORDIC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for BAVARIAN NORDIC (OTCMKTS:BVNRY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: N/A

Analysts' Ratings History for BAVARIAN NORDIC (OTCMKTS:BVNRY)
DateFirmActionRatingPrice TargetDetails
9/15/2017Maxim GroupReiterated RatingBuy -> HoldView Rating Details
10/19/2016Cowen and CompanyReiterated RatingBuyView Rating Details
9/19/2016Piper Jaffray CompaniesReiterated RatingBuyView Rating Details
(Data available from 9/25/2015 forward)


Earnings History by Quarter for BAVARIAN NORDIC (OTCMKTS BVNRY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/25/2017Q2 2017$0.14$0.07$50.65 million$58.68 millionViewN/AView Earnings Details
5/4/2017Q1 2017$0.04($0.01)$37.88 million$28.33 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Current Year EPS Consensus Estimate: $2.17 EPS
Next Year EPS Consensus Estimate: $1.16 EPS


No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for BAVARIAN NORDIC (OTCMKTS:BVNRY)
No insider trades for this company have been tracked by


DateHeadline logoBavarian Nordic Provides Update on its Universal RSV Vaccine - September 21 at 11:24 AM logoCancer vaccines, long considered failures, are hot again - September 15 at 5:13 PM logoBavarian Nordic (BVNRY) Rating Lowered to Hold at Maxim Group - September 15 at 9:12 AM logoBavarian Nordic to Host Capital Markets Day in New York City - September 14 at 10:36 PM logoBavarian Nordic (BVNRY) Posts Earnings Results - August 26 at 10:14 AM logoBavarian Nordic A/S Announces Major Shareholder Notification from Johnson & Johnson Innovation - Inc. - August 22 at 5:26 PM logoBavarian Nordic Announces Closing of Transaction with Janssen Pharmaceuticals, Inc. and Issue of Shares to Johnson & Johnson Innovation - JJDC, Inc. - August 21 at 9:45 PM logoBavarian Nordic (BVNRY) to Release Quarterly Earnings on Friday - August 21 at 9:02 AM logoBavarian Nordic A/S: Bavarian Nordic Announces Subscription Price and Number of Shares to be Issued to Johnson & Johnson Innovation - JJDC, Inc. - August 10 at 3:02 AM logoBavarian Nordic Announces Additional Details Regarding the Issue of Shares to Johnson & Johnson Innovation - JJDC, Inc. - July 27 at 3:55 AM logoBavarian Nordic Issues Warrants to Newly Appointed Member of the Executive Management - July 3 at 9:54 PM logoBavarian Nordic Announces Positive Data from Ongoing Phase 2 Study Investigating a Universal RSV Vaccine - June 27 at 4:20 PM logoBavarian Nordic - Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program - May 19 at 9:00 PM logoBavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme Obligations - May 18 at 4:02 PM logoBavarian Nordic Spon (BVNRY) Cut to "Hold" at Zacks Investment Research - May 16 at 5:16 PM logoBavarian Nordic Spon (BVNRY) Posts Earnings Results, Misses Estimates By $0.05 EPS - May 5 at 2:52 PM logoBavarian Nordic: A Stock You Should Not Miss In 2017 - April 7 at 8:47 AM logoHealthcare Sector Survives Europe's Slide - April 7 at 8:47 AM logoBavarian Nordic A/S - Notice Convening Ordinary General Meeting - April 3 at 9:29 PM logoZacks Investment Research Upgrades Bavarian Nordic Spon (BVNRY) to Buy - March 20 at 5:39 PM logoBavarian Nordic Announces Annual Report 2016 - March 15 at 4:25 PM logoTherapy Focus - Against The Odds, Cancer Vaccines Plough On - February 28 at 1:48 PM logoBavarian Nordic A/S: Bavarian Nordic Provides Update on Anticipated Timing of PROSPECT Study - January 5 at 4:31 PM logoBavarian Nordic Upgrades its Expectations for 2016 Year-end Cash Preparedness - January 3 at 5:37 PM logo7:04 am Bavarian Nordic A/S initiates a clinical trial combining its cancer immunotherapy candidate CV301 with the anti-PD-1 drug Opdivo from Bristol-Myers Squibb (BMY) - December 29 at 9:28 PM logo7:02 am Bavarian Nordic A/S announces 'positive' top-line results from first-in-man phase 1 trial of vaccine indicated for respiratory syncytial virus - May 23 at 7:02 AM logoBristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for PROSTVAC®, a Prostate-Specific Antigen-Targeting Cancer Immunotherapy - March 4 at 1:30 AM



BAVARIAN NORDIC (BVNRY) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by Staff